Parkinson’s Disease Treatment

Parkinson's disease treatmentParkinson’s Disease Treatment: Please note that we only treat early onset Parkinson’s Disease – recently diagnosed. At our Guardian featured clinic we focus on the underlying issues and not just the symptoms in our Parkinson’s Disease treatment.

What is Parkinson’s Disease?

One person in every 500 has Parkinson’s (PD). That’s about 127,000 people in the UK.

Parkinson’s disease (PD) is a progressive neurodegenerative disease that affects one million people in the United States.

Most people who get Parkinson’s are aged 50 or over but younger people can get it too. Parkinson’s disease is characterised by slow movement, muscular rigidity and resting tremor. In addition, depression, sleep disturbances and frequently dementia characterise this disease. The pathology of PD indicates a progressive loss of the dopamine neurons of the substantia nigra together with the presence of Lewy bodies and alpha-synuclein. More extensive brain degeneration also occurs, from the medulla oblongata to the cerebral cortex. Inflammation has also been associated with Parkinson’s.

The development of Parkinson’s has been proposed to be due to multiple genetic and neurotoxic events that produce oxidative damage and cell death. In the case of Parkinson’s the relevant targets of toxic events are neuromelanin-containing dopaminergic neurons of the substantia nigra.

A case-control study indicated that multiple environmental factors and genetic background were statistically related risk factors for the disease. Prominent among these were long-term toxic exposures and trauma early in life. For example, early life exposure to brain injury, chemicals and/or infections may initiate a cyclic inflammatory process involving oxidative damage, excitotoxicity, mitochondrial dysfunction and altered proteolysis that later in life results in substantia nigra neuron death.

A role for chronic infections in PD pathogenesis has been proposed. One infection found in PD that has aroused considerable interest is the presence of chronic gastrointestinal Helicobacter pylori. Indeed, treatment of this infection offers relief to late stage cachexia in PD patients receiving L-dopa. Helicobacter pylori-infected PD patients showed reduced L-dopa absorption and increased clinical disability, whereas treatment of this infection increased L-dopa absorption and decreased clinical disability. H. pylori may not be directly involved in the pathogenesis of PD, but its systemic presence could affect the progression and treatment of PD, probably by stimulating inflammation and autoimmunity.

Chronic infections in PD have been linked to inflammation and autoimmune responses. Experimental models of PD have been developed using neurological viral or bacterial infections to initiate the pathogenic process. Spirochetes have also been found in Lewy bodies of PD patients. Other infections, such as viral encephalitis, AIDS-associated opportunistic infections of the basal ganglia, coronavirus, among other infections, have been found in PD and could be important in stimulating inflammation and autoimmune responses.

It has been stressed that additional research will be necessary to establish whether a causal link exists between PD and chronic infections.

Our Approach to Parkinson’s Disease Treatment

Our approach to early onset Parkinson’s is to carefully choose functional medicine tests and chronic infection tests for each patient and formulate a treatment plan based on the test results, using non pharmaceutical medicine, to meet each patient’s unique needs.

We also address any gut issues, which are often associated with this condition.


Parkinson Disease. Halli-Tierney AD, Luker J, Carroll DG.Am Fam Physician. 2020 Dec 1;102(11):679-691.PMID: 33252908
Parkinson’s Disease. Reich SG, Savitt JM.Med Clin North Am. 2019 Mar;103(2):337-350. doi: 10.1016/j.mcna.2018.10.014. Epub 2018 Dec 3.PMID: 30704685 Review.
Pharmacological treatment of Parkinson disease: a review. Connolly BS, Lang AE.JAMA. 2014 Apr 23-30;311(16):1670-83. doi: 10.1001/jama.2014.3654.PMID: 24756517 Review.
Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). Stocchi F, Marconi S.Clin Neuropharmacol. 2010 Jul;33(4):198-203. doi: 10.1097/WNF.0b013e3181de8924.PMID: 20414107 Review.
Parkinson’s disease: making the diagnosis, selecting drug therapies. Scharre DW, Mahler ME.Geriatrics. 1994 Oct;49(10):14-6, 20-3.PMID: 7926845

If you would like to book an appointment

Contact Deborah’s Medical Secretary for an appointment